During the last decade, researchers have shown an increased interest in neuroprotection, resulting in a large volume of published studies investigating neuroprotective or disease-modifying agents. This emphasis has raised high expectations for novel neuroprotective therapeutic options for PD that until now have not been met [6]. However, this does not mean that all this research has not delivered results, rather, the high expectations have clouded gradual advancements [7]. Although disease-modifying therapies have not yet found their way to clinical practice, a substantial number of compounds have been identified as neuroprotective in preclinical studies. Since most physicians rarely access or appraise scientific evidence directly from research results [8], most neurologists have overlooked preclinical improvements, resulting in lowered expectations and misplaced doubts about neuroprotection.
During the last decade, researchers have shown an increased interest in neuroprotection, resulting in a large volume of published studies investigating neuroprotective or disease-modifying agents. This emphasis has raised high expectations for novel neuroprotective therapeutic options for PD that until now have not been met [6]. However, this does not mean that all this research has not delivered results, rather, the high expectations have clouded gradual advancements [7]. Although disease-modifying therapies have not yet found their way to clinical practice, a substantial number of compounds have been identified as neuroprotective in preclinical studies. Since most physicians rarely access or appraise scientific evidence directly from research results [8], most neurologists have overlooked preclinical improvements, resulting in lowered expectations and misplaced doubts about neuroprotection.
การแปล กรุณารอสักครู่..